Dr Bene Ekine-Afolabi is a research associate in the HSB, who graduated with a degree in Applied Biology (Medical Microbiology Option) from Rivers State University of Science & Technology, then an MRes degree from University of East London, and PhD from Middlesex University. She also worked as associate lecturer at Biochemistry Department, Ladoke Akintola University, Ogbomosho-Nigeria, and at Middlesex University, Barnet-London, United Kingdom. Trained in practical approach to toxicology in drug development (American College of Toxicology/British Toxicology Society), her research areas include Microbiology, Molecular Biology, Cancer Research, infectious diseases. Her current focus of research is on the investigation of molecular mechanism of colorectal cancer development, EMT, and cell death, as well as COVID-19. Bene was awarded part sponsored training in High Impact Cancer Research & Therapeutic and was awarded Distinction by Harvard University (Harvard Medical School). Recently (November 2021), Bene has been awarded a sponsored course by Harvard Medical School continue Education, in Mental Wellness For Health Professionals:COVID-19 Response & Strategies For The Future. She is authoring a Chapter in Springer Book series: Cancer and Immunology, which is due for publication in 2022. Bene is on Editorial Board of Journal of Modern Medicine, and Cancer Research Journal. Her current project involves lead compound optimization in the development of novel therapeutic for colorectal cancer and COVID-19. She is Founder & CEO of ZEAB Therapeutic LTD.